Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 38%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Icon is a leading global contract research organization with a strong track record of profitability and a solid financial position. Their impressive commercial performance and positive outlook, along with a focus on growing net business wins and profitability, make them a strong long-term investment in the growing biopharma industry. While there may be potential risks in government regulations and stagnant outsourcing, Icon's strong ESG performance and continued growth make it a favorable investment option.

Bears say

Icon is facing headwinds related to higher-than-expected passthrough costs, which are outpacing the initial guidance and creating uncertainty around reported margins. The company's exposure to large pharma clients should insulate it from the recent trend of clinical trial terminations among smaller biotech firms. However, as suspensions and cancellations continue to increase in the early-stage programs, this may impact ICLR's bookings in the future. Additionally, the acquisition of PRA Health Sciences has positioned ICLR as the second-largest clinical stage CRO, which could result in an improvement in operational performance going forward.

ICON (ICLR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 38% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 13 analysts, ICON (ICLR) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.